(Q47948560)
Statements
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment (English)
Miguel Canales
Montse Cortés
M Jesus Vidal
Joan Bargay
José L Bello
José J Sánchez
José F Tomás
Eva Donato
Secundino Ferrer
Dolores Caballero
GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea)